Perrigo Company plc is a leading global provider of over-the-counter (OTC) healthcare products. Founded in 1887, the company is headquartered in Dublin, Ireland. Perrigo's main products and services include a wide range of OTC healthcare and nutritional products.

It offers products in categories such as cough and cold, skincare, pain relief, and vitamins and supplements. The company's portfolio includes popular brands like Ricola, Sudafed, and Clear Eyes. In addition to OTC products, Perrigo also manufactures generic prescription pharmaceuticals, active pharmaceutical ingredients, and animal healthcare products.

Operating on a global scale, Perrigo has a strong presence in North America, Europe, and other international markets. It operates through a number of subsidiaries, including Perrigo Company, Perrigo Israel Pharmaceuticals Ltd., and Perrigo Mexico. The company has also formed strategic partnerships and joint ventures with various organizations to expand its global reach.

Perrigo holds a strong market position, with global sales of over $4 billion annually. The company is a recognized leader in the OTC healthcare industry and competes with other major players such as Johnson & Johnson, GlaxoSmithKline, and Bayer. In recent years, Perrigo has made significant strategic changes and achieved noteworthy milestones.

In 2017, the company sold its generic prescription pharmaceutical business to focus on its core OTC and nutritional products. It has also made acquisitions to strengthen its product lineup, including the purchase of Omega Pharma, a leading European OTC healthcare company. As of the latest available information, Perrigo continues to grow and innovate in the healthcare industry.

The company remains committed to providing affordable, quality healthcare products to consumers worldwide